Mannkind (MNKD) Non-Current Assets (2010 - 2026)
Mannkind (MNKD) reported Non-Current Assets of $493.2 million for Q1 2026, up 261.6% year-over-year from $136.4 million in Q1 2025, and down 1.47% quarter-over-quarter from $500.6 million in Q4 2025.
Mannkind (MNKD) Non-Current Assets (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Non-Current Assets data on file, last reported at $493.2 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $493.2 million, up 261.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 144.46% YoY), and the FY2025 annual result was $500.6 million, up 298.77% from the prior year.
- Non-Current Assets declined to $493.2 million in Q1 2026 per MNKD's latest filing, from $500.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $500.6 million in Q4 2025 and troughed at $60.4 million in Q4 2022.
- A 5-year average of $152.0 million and a median of $117.9 million in 2024 frame the typical range for Non-Current Assets.
- On a YoY basis, Non-Current Assets climbed as much as 299.66% in 2022 and fell as far as 40.61% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $60.4 million in 2022, then soared by 68.59% to $101.8 million in 2023, then increased by 23.31% to $125.5 million in 2024, then soared by 298.77% to $500.6 million in 2025, then slipped by 1.47% to $493.2 million in 2026.
- Business Quant data shows MNKD's Non-Current Assets at $493.2 million in Q1 2026, $500.6 million in Q4 2025, and $135.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 493.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 493.24 Mn |
| Dec 31, 2025 | 500.60 Mn |
| Sep 30, 2025 | 135.80 Mn |
| Jun 30, 2025 | 132.67 Mn |
| Mar 31, 2025 | 136.40 Mn |
| Dec 31, 2024 | 125.54 Mn |
| Sep 30, 2024 | 136.54 Mn |
| Jun 30, 2024 | 117.90 Mn |
| Mar 31, 2024 | 97.78 Mn |
| Dec 31, 2023 | 101.81 Mn |
| Sep 30, 2023 | 94.75 Mn |
| Jun 30, 2023 | 83.19 Mn |
| Mar 31, 2023 | 74.84 Mn |
| Dec 31, 2022 | 60.39 Mn |
| Sep 30, 2022 | 75.46 Mn |
| Jun 30, 2022 | 92.32 Mn |
| Mar 31, 2022 | 124.05 Mn |
| Dec 31, 2021 | 101.67 Mn |
| Sep 30, 2021 | 79.00 Mn |
| Jun 30, 2021 | 72.89 Mn |